AstraZeneca Pharma India Ltd approves Q2 FY27 results, reporting revenue of ₹729.1 crore and net profit of ₹62.3 crore
- Revenue rose 30.4% year on year and 6.8% sequentially; net profit increased 14.9% year on year and 64.4% sequentially.
- Q2 exceptional expense was ₹14.96 crore, including a BBMP interest provision and manufacturing-site closure costs; limited-review conclusion was unmodified.
- Board approved Krishnamurthy Narayanan Iyer as independent director, Atul Tandon as CFO, a role change for Nitin Bindal, and Kumaran Krishnan as Medical Director, with changes effective on specified dates in November and December 2026.